

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药  
3SBIO INC.

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1530)**

**(Convertible Bonds Code: 40285)**

## **OVERSEAS REGULATORY ANNOUNCEMENT RELATING TO THE FULL YEAR RESULTS OF SUNSHINE GUOJIAN**

This announcement is made by 3SBio Inc. (the “**Company**”, together with its subsidiaries (collectively referred to as the “**Group**”)) pursuant to Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.\* (三生國健藥業(上海)股份有限公司) (“**Sunshine Guojian**”), a subsidiary of the Company whose shares are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688336), dated 18 January 2021 in relation to the profit warning of Sunshine Guojian’s full year financial results (the “**Sunshine Guojian Announcement**”).

The Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information provided in the Sunshine Guojian Announcement and the preliminary assessment by the financial department of Sunshine Guojian, it is expected that there will be a notable reduction of financial contribution by Sunshine Guojian to the Group for the year ended 31 December 2020 (“**FY2020**”) as compared to that for the year ended 31 December 2019 (“**FY2019**”) from approximately one-fourth of the contribution to the Group’s revenue and net profits (after the extraordinary profits and losses are excluded) for FY2019 to a much smaller amount of contribution for FY2020.

Based on the preliminary information available to the Company, Sunshine Guojian is expected to record a net loss attributable to the owners of the Company in the region of RMB194 million to RMB224 million (or RMB192 million to RMB222 million after the extraordinary profits and losses are excluded) for FY2020, which was mainly attributable to (i) the decrease of revenue due to the impact of COVID-19 pandemic and the intensifying competition in respect of Sunshine Guojian's key product Yisaipu® ( 益賽普 ) (“**Yisaipu**”); and (ii) the downward price adjustment of Yisaipu as disclosed in Sunshine Guojian's announcement on the Shanghai Stock Exchange dated 21 October 2020 and as referred to in the Company's overseas regulatory announcement dated 21 October 2020. The Sunshine Guojian Announcement can be found on the website of the Shanghai Stock Exchange at <http://www.sse.com.cn/assortment/stock/list/info/announcement/index.shtml?productId=688336>.

Save and except for Sunshine Guojian's Yisaipu, the Company confirms that based on the information that is available at this time, it does not expect there to be any other material change or impact on the sales and financial performance of the other major products of the Group for FY2020. As at the date of this announcement, the Group is still in the process of preparing the unaudited condensed consolidated results of the Group for FY2020. The information contained in this announcement is provided only based on the preliminary assessment of the unaudited financial information of Sunshine Guojian with reference to the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditors of the Company or reviewed by the audit committee of the board of directors of the Company (the “**Board**”) and may be subject to adjustments arising from further internal review by the Board and the auditors of the Company where necessary.

Shareholders and potential investors are advised to read carefully the results announcement of the Group for FY2020, which is expected to be published by the end of March 2021.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenyang, the PRC  
18 January 2021

*As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.*

\* *For identification purposes only*